Ethiodized oil
- Generic Name
- Ethiodized oil
- Brand Names
- Lipiodol, Lipiodol Ultra Fluide
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 8008-53-5
- Unique Ingredient Identifier
- KZW0R0686Q
- Background
Ethiodized oil is used by injection as a radio-opaque contrast agent. The composition of the oil is comprised of iodine combined with ethyl esters of fatty acids of poppyseed oil. And although these esters are primarily as ethyl monoiodostearate and ethyl diiodostearate, the actual, specific structure is unknown.
- Indication
For use as a radio-opaque medium for hysterosalpingography and lymphography, and as an antineoplastic agent when part of the iodine is 131-I. It is also used in follow-up imaging for chemoembolization.
- Associated Conditions
- Hepatocellular Carcinoma
- Associated Therapies
- -
Effectiveness of Drug Eluting TACE in Primary HCC
- Conditions
- Interventions
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 75
- Registration Number
- NCT04048317
Localization for Deep Lung Nodules: Microcoil Versus Contrast Injection
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2018-12-04
- Target Recruit Count
- 60
- Registration Number
- NCT03617029
- Locations
- 🇨🇳
National Taiwan University Hospital, Hsin-Chu Branch, Taipei, Hsin-Chu County, Taiwan
Endometrial Effects of Lipiodol
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Target Recruit Count
- 20
- Registration Number
- NCT03542331
- Locations
- 🇧🇪
Universitair Ziekenhuis Brussel, Brussel, Belgium
Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 13
- Registration Number
- NCT02762266
- Locations
- 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
🇺🇸Stanford University, School of Medicine, Palo Alto, California, United States
Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 198
- Registration Number
- NCT02755311
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2016-01-01
- Lead Sponsor
- Second Military Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT02638857
- Locations
- 🇨🇳
Eastern Hepatobiliary Surgery Hospital, Shanghai, China
Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation
- Conditions
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 256
- Registration Number
- NCT02631499
- Locations
- 🇨🇳
Nantong Tumor Hospital, Nantong, Jiangsu, China
🇨🇳The First Affiliated Hospital of Soochow University, Soochow, Jiangsu, China
🇨🇳Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-10-23
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Guangxi Medical University
- Registration Number
- NCT02585479
Lipiodol Localization for Ground-glass-opacity Minimal Surgery
- Conditions
- Interventions
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- Severance Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT02180568
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
- Target Recruit Count
- 320
- Registration Number
- NCT01959061
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.